Antibody-directed Toxic Enzyme Fusion Proteins

Creative Biolabs provides customized antibody-directed toxic enzyme fusion proteins development services with our advanced technology platforms. Our professional scientists have extensive experience in antibody production, synthetic chemistry, and bio-conjugation. We are committed to providing high-quality services to promote the development of innovative cancer treatments by using antibody-directed toxic enzyme fusion proteins.

Antibody-enzyme Fusion Proteins

There are two different antibody-enzyme systems used in cancer therapy, namely antibody-directed enzyme prodrug therapy (ADEPT) and antibody-enzyme fusion proteins. The essential difference between the two systems is that the enzyme component can be cytotoxic or, when localized, used to activate a prodrug. The key feature of antibody-enzyme fusion proteins is that the antibody is used to internalize the toxic enzyme into the tumor cell, activating cell-death processes. This system has been largely applied to cancer research.

Toxic Enzyme

The enzyme is toxic in its own right when used as direct therapeutics. Some of the most frequently used toxic enzymes are angiogenin immunoRNases, HPR immunoRNases, onconase and RapLR1, bovine seminal RNase and so on. For example, GrB is responsible for targeting and activating initiating many pathways, such as direct activation of the caspase via procaspase 8, indirect activation of the caspase cascade via procaspase-9 and cytochrome, thus further amplifying the signals leading to apoptosis. Besides, HPR has been shown to bind strongly to dsRNA and affect its regulatory functions.

Mechanism of GrB-antibody fusion protein. Fig.1 Mechanism of GrB-antibody fusion protein. (Andrady, 2011)

Advantages of Antibody-enzyme Fusion Proteins

In contrast to conventional chemotherapy, antibody-enzyme fusion proteins have demonstrated superior tumor: healthy tissue ratios and relatively low toxicity. At present, antibody-enzyme conjugates are attractive molecules for cancer treatment and many of them have already achieved good results. For instance, onconase has a naturally high selectivity for cancer cells and its antibody-onconase chemical conjugates are currently in Phase III clinical trials for the treatment of malignant mesothelioma.

Creative Biolabs is dedicated to helping our clients design and prepare highly customized antibody-directed toxic enzyme fusion proteins. With the novel technique platform and professional experiment services, Creative Biolabs gets ready to provide you with the best services in a time and cost-efficient way. Please feel free to contact us for more details.


  1. Andrady, C.; et al. Antibody-enzyme fusion proteins for cancer therapy. Immunotherapy. 2011, 3(2), 193-211.

For Research Use Only. NOT FOR CLINICAL USE.

Related Sections

Online Inquiry
*E-mail Address:
*Products or Services Interested:
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us